Corrigendum to "Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes" [Immunol. Lett. 107 (2006) 58-62] (DOI:10.1016/j.imlet.2006.07.009);Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes

Immunology Letters

Volumn 107, Issue 1, 2006, Pages 58-62

  Elluru, SriRamulu ^a,b   Van Huyen, Jean Paul Duong ^c   Bayry, Jagadeesh ^a   Delignat, Sandrine ^a   Prost, Fabienne ^a   Ephrem, Amal ^a   Siberil, Sophie ^a   Misra, Namita ^a   Lacroix Desmzes, Sebastien ^a   Kazatchkine, Michel D ^a   Kaveri, Srini V ^a  

^a INSERM   (France)

^b Université de Technologie   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Caprylate; HUVEC; Inflammation; Intravenous immunoglobulin; IVIG C; IVIG SD

Indexed keywords

DETERGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; OCTANOIC ACID; SOLVENT; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN SECRETION; VIRUS INACTIVATION;

EID: 33748308702     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2006.11.003     Document Type: Erratum

References (19)

1. Carlos T.M., and Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood 84 (1994) 2068-2101
2. Munro J.M., Pober J.S., and Cotran R.S. Tumor necrosis factor and interferon-gamma induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol 135 (1989) 121-133
3. Osborn L., Hession C., Tizard R., Vassallo C., Luhowskyj S., Chi-Rosso G., et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59 (1989) 1203-1211
4. Scholz D., Devaux B., Hirche A., Potzsch B., Kropp B., Schaper W., et al. Expression of adhesion molecules is specific and time-dependent in cytokine-stimulated endothelial cells in culture. Cell Tissue Res 284 (1996) 415-423
5. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
6. Xu C., Poirier B., Van Huyen J.P., Lucchiari N., Michel O., Chevalier J., et al. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am J Pathol 153 (1998) 1257-1266
7. Trejo S.R., Hotta J.A., Lebing W., Stenland C., Storms R.E., Lee D.C., et al. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 84 (2003) 176-187
8. Lebing W., Remington K.M., Schreiner C., and Paul H.I. Properties of a new intravenous immunoglobulin (IVIG-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 84 (2003) 193-201
9. Bayry J., Lacroix-Desmazes S., Hermine O., Oksenhendler E., Kazatchkine M.D., and Kaveri S.V. Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am J Med 118 (2005) 1439-1440
10. Korneyeva M., Hotta J., Lebing W., Rosenthal R.S., Franks L., and Petteway Jr. S.R. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 30 (2002) 153-162
11. Ballow M., Berger M., Bonilla F.A., Buckley R.H., Cunningham-Rundles C.H., Fireman P., et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IVIG-C, 10% (Gamunex, 10%). Vox Sang 84 (2003) 202-210
12. Nakatani K., Takeshita S., Tsujimoto H., Kawamura Y., Tokutomi T., and Sekine I. Circulating endothelial cells in Kawasaki disease. Clin Exp Immunol 131 (2003) 536-540
13. Krause I., Wu R., Sherer Y., Patanik M., Peter J.B., and Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 12 (2002) 133-139
14. Roifman C.M., Schroeder H., Berger M., Sorensen R., Ballow M., Buckley R.H., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 3 (2003) 1325-1333
15. Mouthon L., Haury M., Lacroix-Desmazes S., Barreau C., Coutinho A., and Kazatchkine M.D. Analysis of the normal human IgG antibody repertoire. Evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissues. J Immunol 154 (1995) 5769-5778
16. Lacroix-Desmazes S., Kaveri S.V., Mouthon L., Ayouba A., Malanchere E., Coutinho A., et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Meth 216 (1998) 117-137
17. Stahl D., Lacroix-Desmazes S., Mouthon L., Kaveri S.V., and Kazatchkine M.D. Analysis of human self-reactive antibody repertoires by quantitative immunoblotting. J Immunol Meth 240 (2000) 1-14
18. Bussel J.B., Eldor A., Kelton J.G., Varon D., Brenner B., Gillis S., et al. IVIG-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 91 (2004) 771-778
19. Zhang G., Lopez P.H., and Sheikh K.A. Comparison of different brands of IVIg in an in vitro model of immune neuropathy. J Neuroimmunol 173 (2006) 200-203